ES3047101T3 - Prevention and/or treatment of neurodegenerative disease - Google Patents
Prevention and/or treatment of neurodegenerative diseaseInfo
- Publication number
- ES3047101T3 ES3047101T3 ES18725605T ES18725605T ES3047101T3 ES 3047101 T3 ES3047101 T3 ES 3047101T3 ES 18725605 T ES18725605 T ES 18725605T ES 18725605 T ES18725605 T ES 18725605T ES 3047101 T3 ES3047101 T3 ES 3047101T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- accordance
- zeaxanthin
- disease
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
| PCT/GB2018/051255 WO2019110951A1 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3047101T3 true ES3047101T3 (en) | 2025-12-03 |
Family
ID=60950313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18725605T Active ES3047101T3 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10835509B2 (https=) |
| EP (2) | EP3644979B1 (https=) |
| JP (2) | JP7824729B2 (https=) |
| KR (1) | KR20200095452A (https=) |
| AU (1) | AU2018379644B2 (https=) |
| BR (1) | BR112020005132A2 (https=) |
| CA (1) | CA3071786C (https=) |
| ES (1) | ES3047101T3 (https=) |
| GB (2) | GB201720119D0 (https=) |
| IE (1) | IE87241B1 (https=) |
| MX (1) | MX2020002458A (https=) |
| RU (1) | RU2020111305A (https=) |
| SG (1) | SG11202000786RA (https=) |
| WO (1) | WO2019110951A1 (https=) |
| ZA (1) | ZA202000558B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
| US12076299B2 (en) * | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
| KR20240008846A (ko) * | 2021-05-17 | 2024-01-19 | 오노 야꾸힝 고교 가부시키가이샤 | 인지 기능을 개선하기 위한 조성물 |
| JPWO2024143060A1 (https=) * | 2022-12-26 | 2024-07-04 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| PL2219478T3 (pl) * | 2007-12-17 | 2017-10-31 | Newtricious Bv | Sposób wytwarzania funkcjonalnego produktu spożywczego na bazie żółtka jaja i produkty otrzymywane tym sposobem |
| GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| HUE038813T2 (hu) * | 2011-07-07 | 2018-11-28 | Howard Foundation Holdings Ltd | Eljárás rontó káprázás javítására |
| DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
| GB201300055D0 (en) | 2013-01-03 | 2013-02-20 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
| US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
| MX2015013624A (es) * | 2013-03-28 | 2016-06-10 | Omniactive Health Technologies Ltd | Efecto neuroprotector de carotenoides en el cerebro. |
| JP6178761B2 (ja) | 2013-07-10 | 2017-08-09 | ライオン株式会社 | 内服剤 |
| US20190314442A1 (en) * | 2016-02-22 | 2019-10-17 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-10 ES ES18725605T patent/ES3047101T3/es active Active
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko active Pending
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 EP EP18725605.2A patent/EP3644979B1/en active Active
- 2018-05-10 JP JP2020521460A patent/JP7824729B2/ja active Active
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en not_active Ceased
- 2018-05-10 EP EP25186112.6A patent/EP4599891A3/en active Pending
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
-
2025
- 2025-10-31 JP JP2025184568A patent/JP2026016698A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201720119D0 (en) | 2018-01-17 |
| GB2568986A (en) | 2019-06-05 |
| IE20180146A1 (en) | 2019-06-12 |
| MX2020002458A (es) | 2020-07-20 |
| CA3071786A1 (en) | 2019-06-13 |
| EP3644979A1 (en) | 2020-05-06 |
| EP4599891A3 (en) | 2025-10-22 |
| SG11202000786RA (en) | 2020-06-29 |
| AU2018379644A1 (en) | 2020-03-19 |
| NZ761512A (en) | 2024-01-26 |
| WO2019110951A1 (en) | 2019-06-13 |
| GB2568986B (en) | 2019-12-18 |
| AU2018379644B2 (en) | 2024-02-08 |
| CA3071786C (en) | 2023-11-14 |
| ZA202000558B (en) | 2021-10-27 |
| RU2020111305A (ru) | 2022-01-10 |
| JP2026016698A (ja) | 2026-02-03 |
| EP4599891A2 (en) | 2025-08-13 |
| EP3644979B1 (en) | 2025-08-06 |
| US20190167624A1 (en) | 2019-06-06 |
| GB201807590D0 (en) | 2018-06-27 |
| JP2021505527A (ja) | 2021-02-18 |
| JP7824729B2 (ja) | 2026-03-05 |
| US10835509B2 (en) | 2020-11-17 |
| KR20200095452A (ko) | 2020-08-10 |
| BR112020005132A2 (pt) | 2020-09-15 |
| IE87241B1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stringham et al. | Lutein across the lifespan: From childhood cognitive performance to the aging eye and brain | |
| Martí et al. | Omega-3 fatty acids and cognitive decline: a systematic review | |
| ES2832734T3 (es) | Mejoras en el rendimiento visual o relacionadas con este | |
| ES3047101T3 (en) | Prevention and/or treatment of neurodegenerative disease | |
| Schalch et al. | Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin–the LUXEA (LUtein Xanthophyll Eye Accumulation) study | |
| Mischoulon et al. | Docosahexanoic acid and ω-3 fatty acids in depression | |
| AU2011260037B2 (en) | Dietary formulations | |
| RU2406411C1 (ru) | Долговременное питание для престарелых | |
| Leung | Macular pigment: new clinical methods of detection and the role of carotenoids in age-related macular degeneration | |
| Demirel et al. | The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study | |
| Bowen et al. | Carotenoids in human nutrition | |
| Bartlett et al. | A randomised controlled trial investigating the effect of lutein and antioxidant dietary supplementation on visual function in healthy eyes | |
| Ferraz et al. | The antidepressant role of dietary long-chain polyunsaturated n-3 fatty acids in two phases in the developing brain | |
| Tan et al. | Roles of macular carotenoids in brain function throughout the lifespan: a review of recent research | |
| US20200197349A1 (en) | Cognitive function | |
| Partinen et al. | Nutrition, sleep and sleep disorders–relations of some food constituents and sleep | |
| HK40130790A (en) | Prevention and/or treatment of neurodegenerative disease | |
| Bone et al. | Efficacy of diacetate esters of macular carotenoids: effect of supplementation on macular pigment | |
| US20190307715A1 (en) | Prevention and/or treatment of neurodegenerative disease | |
| Takeda et al. | Effects of mayonnaise on postprandial serum lutein/zeaxanthin and β-carotene concentrations in humans | |
| Abreu-González et al. | Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products | |
| Galvin | Medical foods and dietary approaches in cognitive decline, mild cognitive impairment, and dementia | |
| HASBAL-CELIKOK | NUTRITIONAL SUPPLEMENTS FOR BRAIN HEALTH | |
| Long et al. | Lutein in Neural Health and Disease | |
| van Kan et al. | Prevention of Alzheimer’s disease: implication of nutritional factors |